Cargando…

Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes

SIMPLE SUMMARY: Biliary tract cancer (BTC) carries a poor prognosis. Most patients with BTC will require ‘systemic’ therapy, treating cancer throughout the body to control the disease and extend life while maintaining or improving the quality of life, but not to cure. There is no standard third-line...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gray, Simon, Letissier, Octave, d’Abrigeon, Constance, Shah, Dinakshi, Wardell, Stephen, Faluyi, Olusola, Lamarca, Angela, Hubner, Richard A., Edeline, Julien, Valle, Juan W., McNamara, Mairéad G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252105/ https://www.ncbi.nlm.nih.gov/pubmed/37297009 http://dx.doi.org/10.3390/cancers15113047

Ejemplares similares

The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms
por: Shah, Dinakshi, et al.
Publicado: (2021)

Targeted Therapies for Perihilar Cholangiocarcinoma
por: Gray, Simon, et al.
Publicado: (2022)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
por: Foy, Victoria, et al.
Publicado: (2023)

Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review
por: Shotton, Rohan, et al.
Publicado: (2021)

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
por: Galdy, Salvatore, et al.
Publicado: (2016)

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
por: Lamarca, Angela, et al.
Publicado: (2020)

Distinguishing Genuine Imperial Qing Dynasty Porcelain from Ancient Replicas by On-Site Non-Invasive XRF and Raman Spectroscopy
por: Colomban, Philippe, et al.
Publicado: (2022)

NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)
por: Craig, Zoe, et al.
Publicado: (2020)

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
por: Lamarca, Angela, et al.
Publicado: (2018)

How I treat biliary tract cancer
por: Lamarca, A., et al.
Publicado: (2022)

The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer
por: Abdul Rahman, Rozana, et al.
Publicado: (2021)

Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment—PanDA)
por: Carnie, Lindsay E., et al.
Publicado: (2023)

Biliary tract cancers: current knowledge, clinical candidates and future challenges
por: Tariq, Noor-ul-Ain, et al.
Publicado: (2019)

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis
por: McNamara, Mairéad G., et al.
Publicado: (2020)

Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis
por: Frizziero, Melissa, et al.
Publicado: (2020)

Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre
por: Clelland, Sarah, et al.
Publicado: (2023)

Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
por: Saavedra, Cristina, et al.
Publicado: (2019)

Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice
por: Lamarca, Angela, et al.
Publicado: (2022)

Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
por: Taboada, Rodrigo G, et al.
Publicado: (2022)

Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer
por: Pihlak, Rille, et al.
Publicado: (2023)

What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature
por: McNamara, Mairéad G, et al.
Publicado: (2022)

Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma
por: Najran, Pavan, et al.
Publicado: (2017)

Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice
por: Lamarca, Angela, et al.
Publicado: (2019)

Patterns of care and treatment outcomes in older patients with biliary tract cancer
por: Horgan, Anne, et al.
Publicado: (2015)

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma
por: McNamara, Mairéad G., et al.
Publicado: (2023)

Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma
por: Weaver, Jamie M. J., et al.
Publicado: (2023)

Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Chiramel, Jaseela, et al.
Publicado: (2017)

Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review
por: Robinson, Matthew D., et al.
Publicado: (2023)

Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice
por: Fulton, Alexander JP, et al.
Publicado: (2019)

Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol
por: Carnie, Lindsay E, et al.
Publicado: (2021)

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
por: Lamarca, Angela, et al.
Publicado: (2018)

The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases
por: Kapacee, Zainul-Abedin, et al.
Publicado: (2022)

Germline mutations in pancreatic cancer and potential new therapeutic options
por: Pihlak, Rille, et al.
Publicado: (2017)

Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary
por: Conway, Alicia-Marie, et al.
Publicado: (2022)

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
por: Megdanova-Chipeva, Vera G., et al.
Publicado: (2020)

The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
por: Wheatley, Roseanna C., et al.
Publicado: (2022)

Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter
por: Exarchou, Klaire, et al.
Publicado: (2022)

Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know
por: Robinson, Matthew D., et al.
Publicado: (2023)

Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours
por: Chiramel, Jaseela, et al.
Publicado: (2020)

Endoscopic palliation of malignant biliary obstruction
por: Canakis, Andrew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_492q06rnr4rvifce8hfktl6k3n